S&P DJI Announces March 2026 Quarterly Rebalance
Filed with ASX · · 7 pages · English
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- EMVision Medical Devices to Present at Australia Investor Day February 26th
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Strong emu Clinical Trial & Program Progress
- First Responder Aeromedical Study Commences
Later from EMvision Medical Devices
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- $3.8m R&D Rebate Received & Overseas Finding Approved
- emu Pivotal Trial Expansion Adds Acute Ischaemia Detection
- EMVision to Receive $1.17M IGP Grant Instalment
- Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices